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1. Introduction 
Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inflammatory skin disease 
(1, 2). Analyses of the cytokine expression profile in skin lesions of AD patients show that 
the Th2-type immune response is dominant in AD inflammation (3, 4). Interleukin-4 (IL-
4), IL-5, and IL-13 are signature cytokines of the Th2-type immune response. Expression 
of IL-4 and IL-13 is significantly high in acute lesions of AD skin; however, it is down-
regulated in chronic lesions. In contrast, expression of IL-5 is more elevated in chronic 
lesions than in acute lesions. High expression of IL-4, IL-5, and IL-13 in AD skins leads to 
high serum levels of IgE and eosinophilia, typical clinical features of AD. In addition to 
IL-5, expression of interferon-┛ (IFN-┛) and IL-12 is elevated in chronic skin lesions of AD. 
IFN-┛ and IL-12 are signature cytokines of Th1-type immune response. It has remained 
unclear why this immune milieu change occurs.  
Based on observations of the predominant Th2-type immune responses in AD patients, 
many studies using model mice or involving genetic association have been performed to 
investigate the role played by Th2-type cytokines in the pathogenesis of AD. It is hoped 
that Th2-type cytokines will prove to be good targets to develop therapeutic agents for 
AD. In this chapter, we focus on these topics; we do not review the details of the 
structures, the signal pathways, or the biological functions of these Th2-type cytokines. 
Please refer to other articles regarding with these subjects (5-10).   
2. Th2-type cytokines in model mice  
Animal models are useful to understand the pathogenesis of AD and to develop therapeutic 
agents for AD. Among various species, mouse models have been primarily used, because 
genetically manipulated mice are available. Mouse models of AD can be categorized into 
three groups (2): (1) mice that spontaneously develop AD-like skin lesions, (2) mice 
epicutaneously sensitized with allergens, and (3) genetically engineered mice. It has been 
reported that several AD model mice that spontaneously develop AD-like skin lesions such 
as Nc/Nga mice (11) and DS-Nh mice (12) show a Th2-type–dominant immune milieu, 
suggesting that Th2-type cytokines are involved in pathogenesis in these mice. However, 
the situation is more complex, because it has been demonstrated that Nc/Nga mice deficient 
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in STAT6, a common critical transcription factor for IL-4 and IL-13 signals, exhibited skin 
lesions comparable to those of STAT6-positive littermates (13). Here, we summarize the 
results of analyses investigating the roles of Th2-type cytokines, using mice epicutaneously 
sensitized with allergens and genetically engineered mice (Table 1).    
 
Category Application Phenotypes References 
Ovalbumin-
sensitized 
mouse 
IL-4–
deficient 
mouse 
Decreased eosinophils
Decreased serum IgE 
No change in thickness of epidermis and dermis 
No change in chemokine expression 
No change in infiltration of CD45+, CD4+,  
or CD8+ cells
15 
IL-5–
deficient 
mouse 
No eosinophil
Thinning of epidermis and dermis 
No change in chemokine expression 
No change in infiltration of CD45+, CD4+,  
or CD8+ cells
15 
Genetically 
engineered 
mouse 
IL-4 
transgenic 
mouse 
Xerosis
Conjunctivitis 
Pruritis 
Presence of Staphylococcus aureus 
Spongiosis 
Acanthosis 
Infiltration of mononuclear cells and eosinophils in 
dermis and epidermis  
Degranulation of mast cells in dermis 
Increased expression of IL-5, IL-13,IL-12p40, IFN-┛, 
TNF-┙, and IL-1┚ 
Increased serum IgE and IgG1 
Increased T cell proliferation 
Increased dendritic cells, macrophages,  
and NK cells in skin and lymphoid organs
16-19 
IL-13 
transgenic 
mouse 
Pruritis
Loss of hair 
Erythema 
Crusting 
Excoriation 
Bacterial pyoderma 
Erosions 
Dry lichenified skin lesion 
Infiltration of macrophages, dendritic cells, 
eosinophils, CD4+ cells, and mast cells 
Increased expression of CCL2/MCP-1, 
CCL5/RANTES, CCL11/Eotaxin, CCL17/TARC,  
CCL22/MDC, CCL27/CTACK, TSL, and VEGF 
Increased serum IgE and IgG1 
Increased systemic immune responses
20 
Table 1. Summary of effects of Th2-type cytokines in model mice 
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2.1 Ovalbumin (OVA)-sensitized mice  
Geha’s group established AD model mice by repeated epicutaneous sensitization to OVA 
(14). These mice manifest AD-like skin lesions including acanthosis, spongiosis, and 
infiltration of neutrophils, lymphocytes, mast cells, and eosinophils into the dermis. 
Expression of Th2-type (IL-4, IL-5 and IL-13) cytokines is up-regulated with little or no 
change of IFN-┛ expression (2, 14). Furthermore, serum levels of total or OVA-specific IgE 
and IgG1 are elevated. This mouse model has been used to investigate involvement of 
various molecules associated with the pathogenesis of AD.   
2.1.1 Application of OVA-sensitized mouse model to IL-4–deficient mice 
The role of IL-4 in OVA-sensitized AD model mice is complex (15). The eosinophil 
numbers decrease in the dermis of OVA-sensitized IL-4–deficient mice showing an 
important role of IL-4 for infiltration of eosinophils. However, the numbers of CD45+, 
CD3+, CD4+, and CD8+ cells and expression of MIP-2, MIP-1┚, IP-10, and RANTES 
increase compared to wild type mice, suggesting that IL-4 has an inhibitory role in 
expression of chemokines to recruit T cells. It is of note that thickness of the epidermis 
and dermis are not changed compared to wild type mice showing that IL-4 has a subtle 
effect on skin thickening. In these mice, total or OVA-specific IgE levels significantly 
decrease, which argues against the roles of IgE in the pathogenesis of this mouse model. 
Correspondingly, OVA-sensitized IgE-deficient mice show no change in histological 
views of the skin tissues, infiltration of CD45+, CD3+, CD4+, and CD8+ cells and expression 
of IL-4, IL-5 and IFN-┛ compared to OVA-sensitized wild-type mice (15), suggesting that 
this mouse model is independent of IgE. Furthermore, the redundancy of IL-4 and IL-13 in 
vivo may be the reason why the effects of IL-4–deficiency on skin thickening are subtle in 
this mouse model.  
2.1.2 Application of OVA-sensitized mouse model to IL-5–deficient mice 
IL-5–deficient mice had virtually no eosinophil (15). These mice sensitized with OVA had 
thinning of the epidermis and dermis compared with wild-type mice. However, infiltration 
of CD45+, CD3+, CD4+, and CD8+ cells and expression of chemokines were equivalent to 
wild-type mice. These results may suggest that IL-5 partially contributes to generating AD-
like lesions in this mouse model.  
2.2 Genetically engineered mice for Th2-type cytokines 
Thus far, transgenic mice that express IL-4 or IL-13 specifically in keratinocytes have mainly 
been generated using keratin promoters. In contrast to the IL-4-deficient mice, these gain-of-
function mice manifest overt skin lesions, which indicates topical overexpression of either 
IL-4 or IL-13 that is sufficient to induce phenotypes similar to AD patients.    
2.2.1 IL-4 transgenic mice  
Chan’s group established and characterized IL-4 transgenic mice in which expression of 
IL-4 is controlled under the promoter of the keratin 14 gene (16-19). These mice are 
normal when they are newborn. However, almost four months after birth, they develop 
AD-like lesions such as xerosis (dry skin), conjunctivitis, and pruritic skin lesions (16). 
Many skin lesions appear in ears, necks, and eyes. Forty-three percent of the mice develop 
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skin lesions within 12 months. Inflammatory skin lesions show the presence of 
Staphylococcus aureus, a common infectious complication and exacerbating factor in human 
AD patients. Histological analyses of the lesions in these mice show spongiosis, 
acanthosis, dermal and epidermal infiltration of mononuclear cells and eosinophils, and 
degranulating mast cells in the dermis. Expression of Th2-type cytokines (IL-5, IL-13), 
Th1-type cytokines (IL-12p40, IFN-┛), and inflammatory cytokines (TNF-┙, IL-1┚) is up-
regulated in the skin lesions of these mice. Enhancement of these cytokines except IL-
12p40 is even observed in the skin, before the disease onset or in the intact skin (17). 
Correspondingly, serum levels of IgE and IgG1 are elevated even before the onset, which 
reflects high expression of IL-4 and IL-13. Afterward, up-regulated serum levels of IgG2a 
are observed, reflecting high expression of IFN-┛ (19). T cells in these mice possess higher 
proliferating capacity in vitro spontaneously or induced by stimulants such as T cell 
receptor triggering or Staphylococcus enterotoxins A and B compared to T cells in wild-
type mice (18). It is of note that the numbers of dendritic cells, macrophages, and NK cells 
increase in the skin tissues and lymphoid organs of these mice, which suggests that 
overexpression of IL-4 in skin tissues modulates antigen-presenting activity in vivo.    
2.2.2 IL-13 transgenic mice 
Zhu’s group established IL-13 transgenic mice in which withdrawal of doxycycline 
induces expression of IL-13 under the control of the promoter region of the keratin 5 gene 
(20). Six to eight weeks after the withdrawal of doxycycline, AD-like skin lesions (i.e. 
pruritis, loss of hair, erythema, crusting, excoriation, bacterial pyoderma, and erosions, 
thereafter dry lichenified skin lesion) appear in these mice. All of the mice develop these 
features within four months. In the skin lesions, F4/80+ cells including macrophages and 
dendritic cells, eosinophils, CD4+ cells, and mast cells are accumulated. Expression of 
various chemokines (CCL2/MCP-1, CCL5/RANTES, CCL11/Eotaxin, CCL17/TARC, 
CCL22/MDC, CCL27/CTACK), TSLP (a critical cytokine correlated with AD at the 
interface of epidermis and immune cells), and VEGF (a potent cytokine for angiogenesis), 
is up-regulated in these mice. Serum levels of IgE and IgG1 are elevated. Furthermore, 
systemic Th2 skewing is enhanced because the lymphocytes in the lymph nodes of these 
mice produce more IL-4 and IL-13 upon stimulation of anti-CD3/CD28 antibody (Ab) 
than do those in the wild-type mice.  
3. Genetic associations of Th2-type cytokines with AD  
An initial linkage analysis in Amish families showed the association of 5q31.1 with serum 
IgE levels (21). This chromosome region contains a cluster of Th2-type cytokine genes. 
Therefore, much attention has been paid to the genetic association of Th2-type cytokine 
genes with atopy (defined as high serum IgE level) or with each specific phenotype of 
allergic diseases. As a result, several single nucleotide polymorphisms (SNPs) on the IL4, 
IL5, and IL13 genes have been shown to be associated with atopy or AD (Table 2). 
Furthermore, SNPs located on the IL4RA and IL13RA1 genes encoding the IL-4 receptor ┙ 
chain (IL-4R┙) and the IL-13R ┙1 chain (IL-13R┙1) and on the STAT6 gene encoding STAT6 
were also reported to be associated with atopy or AD. IL-4R┙ is a component of both type I 
IL-4R and type II IL-4R/IL-13, whereas IL-13R┙1 is a component of type II IL-4R/IL-13 
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(Figure 1). STAT6 is a transcriptional factor critical for IL-4 or IL-13 signals. The association 
of the IL13, IL4RA, and STAT6 genes with IgE is confirmed by recent Genome Wide 
Association Studies (22, 23). 
 
Gene Variant Association Function References 
IL4 -590C/T AD Change in IL-4 production 24-26 
IL13 
Arg110Gln  
(Arg130Gln, G4257A)
AD 
Serum IgE 
specific anti-
allergen IgE 
Lower affinity with the IL-
13R ┙2 chain 
Enhanced stability 
Transduction of stronger 
signal via IL-13R┙1 
28-36 
-1055C/T 
('-1111C/, -1024C/T)
AD 
Serum IgE 
specific anti-
allergen IgE 
Change in IL-13 
production 
34, 37-40 
IL4RA 
Gln576Arg 
(Gln551Arg) 
Hyper IgE 
syndrome 
AD 
Decreased binding to 
SHP-1 
Increased STAT6 activation 
41, 42 
IL13RA1 1398A/G Serum IgE  27 
STAT6 
2964G/A Serum IgE  43 
in18SNP1C/T 
Serum IgE 
Eosinophil 
number 
 44 
GT repeat in exon1 
Serum IgE 
Eosinophil 
number 
 44 
IL5 -703C/T 
Serum IgE 
Eosinophil 
number 
 45 
Table 2. Summary of genetic associations in Th2-type cytokines and their related molecules 
3.1 IL-4 gene 
There exists a SNP in the promoter of the IL4 gene (-590C/T). This SNP was originally 
reported to be associated with bronchial asthma (24) and is thought to affect the binding 
activities to NFAT, resulting in modulating IL-4 production. Transmission disequilibrium 
testing shows a significantly preferential transmission of the T allele in AD patients (25). 
Another group confirmed the association of this SNP with AD (26). 
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Fig. 1. The receptor structures and signal pathways of IL-4 and IL-13.  
IL-4 binds to type I IL-4R or type II IL-4R/IL-13R, and IL-13 binds to type II IL-4R/IL-13R. 
Type I IL-4R and type II IL-4R/IL-13R are composed of IL-4R┙ and the IL-2R ┛ chain 
(common ┛) or IL-4R┙ and IL-13R┙1, respectively. Engagement of the receptors activates Jak 
kinases followed by activation of STAT6. 
3.2 IL-13 gene 
There exist several SNPs on the IL13 gene. Thus far, two of them (Arg110Gln, also referred 
to as Arg130Gln or G4257A; and -1055C/T, also referred to as -1111C/T or -1024C/T) are 
reported to be associated with atopy or AD. We and other groups reported the genetic 
association of Arg110Gln with bronchial asthma (27), serum IgE levels (28, 29), and AD (29). 
This SNP causes exchange of arginine at the 110 (130) amino acid for glutamine. Several 
functional differences between the arginine type and the glutamine type have been 
demonstrated (30-32): (1) The glutamine type has lower affinity with the IL-13R ┙2 chain, a 
decoy receptor for IL-13, than the arginine type. (2) The glutamine type has enhanced 
stability over the arginine type (3). The glutamine type transduces a stronger signal via IL-
13R┙1, a functional receptor for IL-13, than the arginine type. All of these results suggest 
that the glutamine type acts more potently in vivo than the arginine type. It has been 
reproducibly demonstrated that this SNP is genetically associated with serum total IgE 
levels (33-35), specific anti-allergen IgE (33, 35), or AD (36). 
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-1055C/T was originally found to be associated with bronchial asthma and positive skin 
tests (37, 38). This SNP is adjacent to the biding site for NFAT; hence, this variant may affect 
the complex formation of transcriptional factors. Reproducible genetic associations of this 
SNP with serum total IgE levels (34, 39), specific anti-allergen IgE (35, 40), or AD (39) have 
been observed. 
3.3 IL-4Rα gene 
The type II IL-4R or the IL-13R is composed of IL-4R┙ and IL-13R┙1. Both IL-4 and IL-13 
bind to this receptor on cell surface, transducing their signals intracellularly (5, 6). Several 
SNPs on the IL4RA gene are known to be genetically associated with atopy or allergic 
diseases. The genetic association of Gln576Arg, also referred as Gln551Arg, was originally 
found in hyper IgE syndrome patients, some of who had severe AD (41). Position 576 is 
adjacent to the tyrosine residue at 575, a binding site for SHP-1, a phosphotyrosine 
phosphatase. Exchange of glutamine for arginine decreases the binding activities for SHP-1, 
resulting in up-regulation of STAT6 activation. The genetic association of this SNP with AD 
was confirmed by another group (42). 
3.4 IL-13α1 gene 
IL-13R┙1 is another component of type II IL-4R/IL-13R, together with IL-4R┙. A SNP in the 
coding region of the IL13RA1 gene, 1398A/G, was reported to be genetically associated with 
serum IgE levels (27). The function of this SNP is unclear because this SNP is a silent one.  
3.5 STAT6 gene 
STAT6 is a transcriptional factor, critical for both IL-4 and IL-13 signals (5, 6). 
Heterodimerization of type I IL-4R or type II IL-4R/IL-13R by binding of IL-4 or IL-13 
activates Jak1, Jak3, or Tyk2, tyrosine kinases associated with IL-4R┙, common ┛, and IL-
13R┙1 respectively, followed by activation of STAT6. Several SNPs on the STAT6 gene, 
2964G/A, in18SNP1C/T, and GT repeat in exon1 were reported to be associated with serum 
IgE levels or with eosinophil numbers (43, 44). 
3.6 IL-5 gene 
A SNP on the IL5 gene (-703C/T) was reported to be associated with the numbers of 
eosinophils in blood and serum IgE levels, but not with AD (45). 
4. Th2-type cytokine – Targeted treatment for AD 
Because of the importance of Th2-type cytokines in the pathogenesis of AD, it has been 
thought that Th2-type cytokines have the potential to be targeted to develop novel agents 
against AD. A clinical trial to administer a humanized anti–IL-5 monoclonal Ab 
(mepolizumab) to AD patients was performed, with a disappointing result (46). To the best 
of our knowledge, no trial targeting IL-4 or IL-13 for AD patients has thus far been 
performed. 
4.1 Antagonist of IL-5 for treatment of AD 
AD patients received 750 mg of humanized anti–IL-5 monoclonal Abs (mepolizumab) 
intravenously twice (at day 0 and 7) (46). Efficacy assessed by SCORAD was observed at 
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day 14 but was not statistically significant. There was no difference in pruritis score between 
mepolizumab- and placebo-administered groups. Even when efficacy was assessed by 
PGA (the Physician’s Global Assessment of Improvement), the numbers showing ‘marked 
improvement’ were not statistically significant. However, it is of note that 4 of 18 (22.2%) 
patients receiving mepolizumab showed ‘marked improvement’. These results can be 
interpreted two ways: one is that the overall efficacy of mepolizumab is not as good as 
expected. The other is that mepolizumab is effective only for limited patients. The latter is 
likely when mepolizumab is administered to patients with bronchial asthma. In the first 
clinical trial, mepolizumab yielded a disappointing result (47, 48). However, it turned out 
that mepolizumab is quite effective for the patients with sputa containing large numbers 
of eosinophils (49, 50). It is important to select patients who are sensitive to certain 
molecular target drugs by so-called ‘companion diagnostics’: in this case, numbers of 
eosinophils in sputum. A companion diagnostic should be found to treat AD effectively 
with mepolizumab. 
5. Conclusion 
In this chapter, we summarized the studies concerned with Th2-type cytokines in the 
pathogenesis of AD from the standpoint of the model mice and genetic association. 
Furthermore, we mentioned a trial in which AD patients were treated by administration of 
neutralizing Abs against IL-5. We hope the information in this review will be useful in 
developing new treatments for AD patients in the future. 
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